39.47
0.45%
-0.18
After Hours:
39.47
Overview
News
Price History
Option Chain
Why BAX Down?
Discussions
Forecast
Stock Split
Dividend History
Baxter International Inc. stock is currently priced at $39.47, with a 24-hour trading volume of 2.74M.
It has seen a -0.45% decreased in the last 24 hours and a -5.91% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $39.56 pivot point. If it approaches the $39.38 support level, significant changes may occur.
Baxter International Inc. Stock (BAX) Financials Data
Baxter International Inc. (BAX) Revenue 2024
BAX reported a revenue (TTM) of $14.95 billion for the quarter ending December 31, 2023, a +2.01% rise year-over-year.
Baxter International Inc. (BAX) Net Income 2024
BAX net income (TTM) was $2.66 billion for the quarter ending December 31, 2023, a +209.17% increase year-over-year.
Baxter International Inc. (BAX) Cash Flow 2024
BAX recorded a free cash flow (TTM) of $1.03 billion for the quarter ending December 31, 2023, a +74.96% increase year-over-year.
Baxter International Inc. (BAX) Earnings per Share 2024
BAX earnings per share (TTM) was $5.22 for the quarter ending December 31, 2023, a +208.07% growth year-over-year.
Baxter International Inc. Stock (BAX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Mason Jeanne K | EVP, Chief HR Officer |
Mar 01 '24 |
Option Exercise |
37.17 |
64,488 |
2,397,019 |
206,778 |
Mason Jeanne K | EVP, Chief HR Officer |
Mar 01 '24 |
Sale |
40.61 |
64,488 |
2,618,858 |
142,290 |
Baxter International Inc. Stock (BAX) Latest News
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
Zacks Investment Research
Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day
Zacks Investment Research
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
Zacks Investment Research
Reasons to Hold Baxter International (BAX) in Your Portfolio
Zacks Investment Research
Assessing Baxter Intl: Insights From 4 Financial Analysts
Benzinga
Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy
Zacks Investment Research
About Baxter International Inc.
Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Cap:
|
Volume (24h):